

Study variables	P value	HR	95% CI for HR	
			Lower	Upper
Age at baseline	<0.01	1.052	1.035	1.070
Race	0.44			
Chinese		1.00		
Indian	0.84	0.96	0.65	1.43
Malay	0.13	1.20	0.95	1.52
Others	0.91	0.97	0.55	1.71
Sex (female)	<0.001	4.15	3.17	5.43
Polyclinic	0.046			
Clinic A		1.00		
Clinic B	0.59	0.92	0.69	1.24

Study variables	P value	HR	95% CI for HR	
			Lower	Upper
Clinic C	0.04	1.34	1.01	1.78
Clinic D	0.27	0.85	0.64	1.13
Clinic E	0.18	1.24	0.91	1.69
Chronic diseases at baseline				
Diabetes mellitus	0.22	3.45	0.48	24.9
Hypertension	0.12	0.71	0.46	1.09
Hyperlipidaemia	0.44	1.73	0.42	7.08
Smoker or ex-smoker	0.45	1.10	0.86	1.42
Clinical parameters				
BMI	0.482	1.008	0.986	1.030
Baseline HbA1c	<0.001	1.144	1.071	1.223
Baseline serum creatinine	<0.001	1.063	1.057	1.069
Baseline SBP	0.735	0.999	0.991	1.006
Baseline DBP	0.037	1.013	1.001	1.026
Albuminuria stage (at baseline)	<0.001			
A1		1		
A2	0.65	1.09	0.76	1.55
A3	0.004	1.77	1.19	2.61
Albuminuria stage (at analysis)	<0.001			
A1		1		
A2	0.72	1.06	0.76	1.49
A3	<0.001	2.22	1.55	3.19
Management parameters				
Received CKD counselling	0.14	1.39	0.89	2.16
Started on SGLT2i	0.49	0.93	0.76	1.14
Change in ACEi/ARB dose from baseline to at analysis	<0.001			
Maintained same dose		1		
Increased dose	0.94	1.01	0.77	1.32
Decreased dose ^a	<0.001	1.92	1.50	2.45

^a Decreased dose includes drug cessation
 ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; BMI: body mass index; CI: confidence interval;
 CKD: chronic kidney disease; DBP: diastolic blood pressure; HR: hazard ratio; Hb1Ac: haemoglobin 1Ac; SBP: systolic blood pressure;
 SGLT2i: sodium-glucose cotransporter-2 inhibitor